Get the Stockscreener App
211.77
0.51%
1.13
Veeva Systems Inc stock is traded at $211.77, with a volume of 81,876.
It is up +0.51% in the last 24 hours and down -8.62% over the past month.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
See More
Previous Close:
$210.64
Open:
$211.53
24h Volume:
81,876
Relative Volume:
0.07
Market Cap:
$34.27B
Revenue:
$2.75B
Net Income/Loss:
$714.14M
P/E Ratio:
48.91
EPS:
4.33
Net Cash Flow:
$1.09B
1W Performance:
-0.92%
1M Performance:
-8.62%
6M Performance:
+0.18%
1Y Performance:
+0.24%
1-Day Range:
$208.34
$212.44
1-Week Range:
$201.54
$219.52
52-Week Range:
$170.25
$258.93
Veeva Systems Inc Stock (VEEV) Company Profile
Name
Veeva Systems Inc
Sector
Industry
Phone
925-452-6500
Address
4280 HACIENDA DRIVE, PLEASANTON, CA
Compare VEEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
211.62 | 34.27B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
52.26 | 9.68B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
41.63 | 6.97B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
79.77 | 6.93B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.27 | 6.24B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Downgrade | Goldman | Buy → Sell |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Dec-04-24 | Initiated | Mizuho | Outperform |
| Nov-19-24 | Initiated | Scotiabank | Sector Perform |
| Oct-08-24 | Initiated | Exane BNP Paribas | Outperform |
| Aug-27-24 | Reiterated | Citigroup | Buy |
| Jul-09-24 | Initiated | BTIG Research | Buy |
| Oct-25-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-23 | Initiated | Jefferies | Buy |
| Jun-28-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Truist | Buy → Hold |
| Feb-23-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-04-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-06-22 | Initiated | Cowen | Market Perform |
| Dec-02-22 | Reiterated | Needham | Buy |
| Oct-31-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-27-22 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | Goldman | Buy |
| Jun-21-22 | Resumed | Guggenheim | Buy |
| Mar-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-28-22 | Initiated | Truist | Buy |
| Jan-07-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-06-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-16-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Resumed | Stifel | Buy |
| Sep-02-21 | Reiterated | BofA Securities | Buy |
| Sep-02-21 | Reiterated | JMP Securities | Mkt Outperform |
| Sep-02-21 | Reiterated | Needham | Buy |
| Sep-02-21 | Reiterated | UBS | Neutral |
| Jul-21-21 | Initiated | Cowen | Outperform |
| Mar-31-21 | Upgrade | UBS | Sell → Neutral |
| Jan-07-21 | Resumed | KeyBanc Capital Markets | Overweight |
| Dec-09-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-14-20 | Resumed | UBS | Sell |
| Aug-28-20 | Reiterated | Needham | Buy |
| Jul-23-20 | Initiated | FBN Securities | Outperform |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Jun-08-20 | Initiated | Citigroup | Buy |
| May-29-20 | Reiterated | Needham | Buy |
| Apr-13-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-19-20 | Initiated | Robert W. Baird | Outperform |
| Feb-14-20 | Initiated | Piper Sandler | Overweight |
| Jan-13-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-27-19 | Reiterated | Canaccord Genuity | Hold |
| Sep-26-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-28-19 | Reiterated | Needham | Buy |
| Jun-07-19 | Initiated | Goldman | Neutral |
| May-30-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-24-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-27-19 | Reiterated | Needham | Buy |
View All
Veeva Systems Inc Stock (VEEV) Latest News
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last? - Yahoo
eClinical Solutions Market Top PlayersMedidata, Veeva Systems, Iqvia Inc., Icon Plc, Signant Health. - openPR.com
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com South Africa
Veeva Systems director Timothy Cabral sells $841,734 in stock - Investing.com
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know - Yahoo Finance
Why Is Veeva (VEEV) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Veeva Systems (VEEV) Benefited in Q4 From Strong Execution - Insider Monkey
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - MSN
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Best Momentum Stocks to Buy for April 3rd - TradingView
Veeva Systems Inc. (NYSE:VEEV) Receives $256.52 Average PT from Brokerages - MarketBeat
Veeva Systems SVP sells shares worth $178,019 - Investing.com Australia
Wall Street Analysts Think Veeva (VEEV) Is a Good Investment: Is It? - MSN
Veeva Systems SVP sells shares worth $178,019 By Investing.com - Investing.com Canada
We Think Veeva Systems' (NYSE:VEEV) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
VEEV Stock Slips Despite New Research Site Clinical Trial System - Yahoo Finance
How UCB and Other Biopharmas Made the Case for Safety Transformation - Veeva
Aligning Medical & Commercial Teams to Drive Product Adoption - Veeva
Veeva Systems (NYSE:VEEV) Unveils New CTMS for Efficient Clinical Trial Management - Yahoo Finance
Veeva Announces Research Site Clinical Trial Management System - Contract Pharma
5 Momentum Stocks to Buy for April Despite a Disappointing March - TradingView
Sell Rating for Veeva Systems Amid Volatile Macroeconomic Conditions and Industry Risks - TipRanks
EVERSANA joins with Veeva in push to 'pharmatise AI' - pharmaphorum
EVERSANA Joins Veeva AI Partner Program - PR Newswire
Top Stock Picks for Week of March 31, 2025 - TradingView
Veeva Systems’ SWOT analysis: cloud software leader faces industry headwinds - Investing.com
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now - MSN
China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market - Investor's Business Daily
What Does the Market Think About Veeva Systems? - Benzinga
Verve: Embracing Digital-First Quality - Veeva
Exponential Growth Expected for Clinical Data Management - openPR
Veeva Systems, Inc. is hiring: Creative Operations Manager in New York - Mediabistro
With EPS Growth And More, Veeva Systems (NYSE:VEEV) Makes An Interesting Case - simplywall.st
Electronic Trial Master File (eTMF) Systems Market Size, Trends - openPR
Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Decentralized Clinical Trials Market to Expand Rapidly Growth - openPR
Raymond James maintains Veeva stock Outperform rating, $285 target - Investing.com
Raymond James maintains Veeva stock Outperform rating, $285 target By Investing.com - Investing.com UK
Decoding Veeva Systems Inc (VEEV): A Strategic SWOT Insight - GuruFocus
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Automation Meets Flexibility: How Veeva Systems Is Disrupting Pharma Tech With AI & CRM Integration! - Smartkarma
Indero Marks 40th Study Live with Veeva RTSM -March 19, 2025 at 07:04 am EDT - Marketscreener.com
Indero Marks 40th Study Live with Veeva RTSM – Company Announcement - Financial Times
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well (NYSE:VEEV) - Seeking Alpha
Veeva Systems Inc. (VEEV): A Bull Case Theory - MSN
Bayer AG: Harmonizing Data for Impactful Campaigns - Veeva
Clinical Data Management Systems (CDMS) Market Next Big Thing: Major Giants- Oracle, Veeva Systems, Parexel - openPR
Veeva (VEEV) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Veeva Systems Inc Stock (VEEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):